Photogeneration of Quinone Methides as Latent Electrophiles for Lysine Targeting by Pérez Ruiz, Raul et al.
 
Document downloaded from: 
 

























Pérez Ruiz, R.; Molins-Molina, O.; Lence, E.; González-Bello, C.; Miranda Alonso, MÁ.;
Jiménez Molero, MC. (02-1). Photogeneration of Quinone Methides as Latent Electrophiles




Subscriber access provided by Kaohsiung Medical University
is published by the American Chemical Society. 1155 Sixteenth Street N.W.,
Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.
Article
Photogeneration of Quinone-Methides as
Latent Electrophiles for Lysine-Targeting
Raul Perez-Ruiz, Oscar Molins-Molina, Emilio Lence, Concepción
González-Bello, Miguel A Miranda, and M. Consuelo Jiménez
J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.8b01559 • Publication Date (Web): 02 Oct 2018
Downloaded from http://pubs.acs.org on October 6, 2018
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society provides “Just Accepted” as a service to the research community to expedite the dissemination
of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in
full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully
peer reviewed, but should not be considered the official version of record. They are citable by the
Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore,
the “Just Accepted” Web site may not include all articles that will be published in the journal. After
a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web
site and published as an ASAP article. Note that technical editing may introduce minor changes
to the manuscript text and/or graphics which could affect content, and all legal disclaimers and
ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or
consequences arising from the use of information contained in these “Just Accepted” manuscripts.
 
 
Photogeneration of Quinone-Methides as Latent Electrophiles for 
Lysine-Targeting 
Raúl Pérez-Ruiz,a, b Oscar Molins-Molina,a Emilio Lence,c Concepción González-Bello,c* Miguel A. 
Miranda,a* M. Consuelo Jiméneza* 
a Departamento de Química/Instituto de Tecnología Química UPV-CSIC, Universitat Politécnica de València, Camino de 
Vera s/n 46071 Valencia (Spain).  
b Photoactivated Processes Unit, IMDEA Energy Institute, Av. Ramón de la Sagra 3, 28935 Móstoles, Madrid (Spain). 
c Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Departamento de Química Or-
gánica, Universidade de Santiago de Compostela, Jenaro de la Fuente s/n, 15782 Santiago de Compostela (Spain). 
 
 
ABSTRACT: Latent electrophiles are nowadays very attractive chemical entities for drug discovery, as they are unreactive unless 
activated upon binding with the specific target. In this work, the utility of 4-trifluoromethyl phenols as precursors of latent electro-
philes − quinone methides (QM) − for lysine-targeting is demonstrated. These Michael acceptors were photogenerated for specific 
covalent modification of lysine residues using human serum albumin (HSA) as a model target. The reactive QM-type intermediates 
I or II, generated upon irradiation of 4-trifluoromethyl-1-naphthol (1)@ HSA or 4-(4-trifluorometylphenyl)phenol (2)@HSA com-
plexes, exhibited chemoselective reactivity towards lysine residues leading to amide adducts, which was confirmed by proteomic 
analysis. For ligand 1, the covalent modification of residues Lys106 and Lys414 (located in sub-domains IA and IIIA, respectively) 
was observed, whereas for ligand 2, the modification of Lys195 (in sub-domain IIA) took place. Docking and molecular dynamics 
simulation studies provided an insight into the molecular basis of the selectivity of 1 and 2 for these HSA sub-domains and the 
covalent modification mechanism. These studies open the opportunity of performing protein silencing by generating reactive lig-
ands under very mild conditions (irradiation) for specific covalent modification of hidden lysine residues. 
INTRODUCTION 
Small organic molecules can undergo bioactivation in vivo, 
which affords electrophilic species able to react with biom-
acromolecules, leading to covalent adducts that trigger unde-
sired toxic effects. This was already described in the 30’s for 
the metabolites of polycyclic aromatic hydrocarbons, which 
were found to be highly reactive intermediates able to attach to 
liver proteins.1 During the 70s, the covalent binding theory of 
xenobiotic-induced liver and lung toxicity emerged, as well as 
the idea that drug-protein adducts are potential haptens able to 
elicit immune-mediated adverse events. Such irreversible 
binding was viewed as a risk factor in drug development, 
either by the direct tissue damage or by the immune responses 
after protein haptenation. However, the last decade has wit-
nessed the renaissance of targeted covalent inhibition in drug 
discovery,2 for example in the successful treatment of cancer 
by covalent epidermal growth factor receptor (EGFR) inhibi-
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tors.3 The enormous advantages of irreversible drugs are asso-
ciated with their high potency, low dosage, extended duration 
of action, selectivity and general applicability.4 These features, 
together with an improved understanding of their potential 
risks, have resulted in a remarkable increase of the number of 
clinical trials, drug approvals and scientific articles in the 
area.4  
In this context, binding and reactivity are the two key steps 
involved in “protein silencing”. The former consists in the 
reversible association between an inhibitor (a high-affinity 
ligand) and its biological target, whereas the latter is the reac-
tion between both partners to form a covalent adduct. Inhibi-
tors of this type usually contain an electrophilic functional 
group that reacts with a close nucleophile on the target. Their 
design is highly challenging because it requires an appropriate 
combination of affinity, reactivity and selectivity, to avoid off-
target effects. Hence, electrophiles that are unreactive unless 
activated upon protein binding (latent electrophiles, LEs) are 
of particular interest in drug development. This constitutes an 
attractive research field, as only few selective and safe LEs 
have been reported.5  
Strategically, targeted covalent inhibition requires the catalytic 
action of a protein to convert a ligand into the corresponding 
LE within the active site (Scheme 1, pathway A). Although 
this is now considered as a validated tool for drug discovery, 
alternative strategies for addressing this issue would be desira-
ble. One interesting possibility could be the utilization of light 
as an external factor to achieve direct formation of LEs from 
the bound ligand, without the need for any catalytic process 
mediated by the protein (Scheme 1, pathway B). 
To inactivate proteins through formation of irreversible ad-
ducts, alkylations or Michael additions are among the most 
frequently employed reactions.4c,d Specifically, quinone 
methides (QMs) are good Michael acceptors that can react 
with the amino acid residues of proteins (commonly Cys) and 
other QM intermediates have been found to modify proteins;6 
in this context QM have been applied as suitable LEs for the 
inhibition of mammalian serine proteases and bacterial serine 
β-lactamases.7 However, the photogeneration of QMs8 within 
proteins has been rarely reported, despite the possibility of 
exciting selectively their precursors under mild conditions. 9 
Trifluoromethyl substituted aromatic moieties are present in a 
number of agrochemicals,10 polymers11 and pharmaceuticals.12 
In general, incorporation of a trifluoromethyl substituent en-
hances the lipophilicity of active compounds and results in a 
better incorporation into target cells. In comparison with other 
halogen-containing compounds, trifluoromethyl derivatives 
are less reactive13,14 and reluctant to biological degradation15. 
However, a number of trifluoromethyl aromatics can be con-
verted into carboxylic acid derivatives in the presence of nu-
cleophiles upon photochemical activation.16 In this regard, the 
photohydrolysis of trifluoromethyl-substituted phenols and 
naphthols has been previously reported to occur through for-
mation of QM intermediates.17 
With this background, we decided to explore the feasibility of 
the targeted covalent inhibition concept through photochemi-
cal generation of LEs and subsequent reaction with targeted 
protein nucleophiles. Compared to cysteine residues,18 target-
ing nucleophilic lysine residues of the binding-sites appears 
more challenging and has been less exploited.19 In this context, 
identification of adducts between 2-hydroxy-4-
trifluoromethylbenzoic acid and the ε-amino groups of the 
lysine residues of ubiquitin under sunlight exposure has been 
recently demonstrated by photophysical and proteomic analy-
sis.20  
Scheme 1. Targeted Irreversible Inhibition Approaches 
 
 
To check whether photogenerated QMs can be appropriate 
LEs for lysine-targeting, we selected 4-trifluoromethyl-1-
naphthol (1) and 4-(4-trifluorometylphenyl)phenol (2) (Chart 
1) as model compounds. The naphthalene and biphenyl chro-
mophores should be advantageous for spectroscopic measure-
ments. As regards the model protein, human serum albumin 
(HSA) was chosen taking into account its availability and dark 
binding capability.21 The obtained results clearly show that 
formation of ground-state complexes between ligands and 
HSA leads ultimately to stable adducts between photogenerat-
ed LEs and lysine residues localized in the binding pockets of 
HSA. 







RESULTS AND DISCUSSION 
The methodological approach to achieve the proposed objec-
tive involved i) characterization of the excited states of 1 and 2 
in solution, both as the free compounds and in the presence of 
proteins, ii) proteomic studies of 1 and 2 irradiated in the 
presence of HSA, to detect covalent photobinding to amino 
acid residues and iii) theoretical calculations, to understand the 
binding modes and the formation of adducts. The obtained 
results are presented below in separated sections.  
Photophysical detection of a complex between trifluoro-
methylphenols 1 and 2 and HSA. First, the absorption and 
emission properties of 1 were determined in acetonitrile and in 
aqueous media, under neutral and alkaline conditions (pH = 
7.4 or pH=12), to ensure predominance of the phenol or the 
phenolate anion in the ground state. A summary of the ob-
tained results is presented in Table 1. It was found that the free 
phenol absorbs at ca. 300 nm and emits at ca. 340 nm, where-
as the corresponding bands of the phenolate displayed maxima 
at ca. 340 and 450 nm, respectively.  
In the case of 2, the free phenol showed absorption and emis-
sion peaking at 270-275 nm and 350-365 nm, respectively. 
The corresponding bands of the phenolate were found at 305 
and 430 nm. Some representative spectra of 1 and 2 under 
different conditions are shown in Figures S1-S3 of the Sup-
porting Information.  
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When the absorption spectrum of 1 was recorded in PBS, in 
the presence of HSA, a new band emerged above 320 nm, 
which increased with increasing concentrations of protein. A 
similar trend was observed for 2 in the presence of HSA, alt-
hough the new band was more intense compared to that of 1 
(Figures S4A,B). In both cases, the new bands were attributed 
to a ground-state complex with HSA. Selective excitation of 
the complexes led to new emission bands centered at λ = 420 
nm (1) or λ = 415 nm (2), which again increased with increas-
ing concentrations of protein (Figure S4C,D) and were differ-
ent from those previously ascribed to the corresponding phe-
nol or phenolate (Figure 1A,B); they were attributed to emis-
sion from the above mentioned HSA complexes. Control 
experiments, consisting on excitation of HSA alone, indicated 
the absence of emission arising from the protein under the 
experimental conditions (Figure S5). The stoichiometry of the 
1@HSA and 2@HSA complexes was determined as 2:1 and 
1:1, respectively, by means of Job plot analysis (SI, Figure 
S6).22 To evidence formation of 1@HSA and 2@HSA com-
plexes, difference spectra, i. e. [1@HSA]-[1+HSA], were 
obtained upon variations of ligand/protein molar ratios (Fig-
ures S7A and S8A). To calculate the binding constants, the 
Benesi-Hildebrand procedure23 (eq. 1, Figures S7B and S8B) 











             Eq. 1º 
 
where Abscomplex is the maximum absorbance of complexes (at 
373 nm for 1 and 315 nm for 2) at different HSA concentra-
tions and εcomplex is the molar absorption coefficient. The hhg-
affinity Kcomplex values, determined from the slope, are 2.4 × 
105 M-1 and 2.8 × 104 M-1, for 1 and 2, respectively. These 
results are consistent with data previously reported for similar 
compounds such as naphthol and hydroxybiphenyl.24   
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Figure 1. Emission (large) and absorption (inset) spectra, record-
ed in PBS (red) and in the presence of 2 equivalents of HSA 
(blue) for 1 (A) and 2 (B), respectively; λexc was 355 nm for 1 and 
324 nm for 2. (C): Normalized transient absorption spectra ob-
tained for 1 (orange) and 2 (black) in PBS in the presence of 5 
equivalents of HSA, upon laser excitation at 355 nm. In all meas-
urements, [1] = 0.05 mM, [2] = 0.05 mM  
Laser flash photolysis of the 1@HSA and 2@HSA 
complexes was also performed upon excitation at 355 nm. In 
both cases, the resulting transient absorption spectra (Figure 
1C) were tentatively ascribed to the expected quinone methi-
des I and II (Chart II), based on the existing data on related 
compounds. Their lifetimes were 0.5 and 8.0 µs, respective-
ly.8h,i 
Photobinding of 1 and 2 to HSA. Irradiation of 1 and 2 in 
aqueous media (λmax = 300 nm) led to the corresponding car-
boxylic acids, in agreement with the previously reported result 
for similar substrates. The accepted mechanism involves 
deprotonation in the singlet excited state, followed by hetero-
lytic C-F bond cleavage to afford a QM-type intermediate (I or 
II, Chart 2).17 
Photolysis of 1@HSA and 2@HSA was performed 
for detecting the possible formation of covalent photoadducts 
([ligand] = 5 × 10−5M; ligand:protein 1:5 molar ratio, air/PBS, 
λmax irr. = 300 nm). The photodegradation process was moni-
tored by fluorescence spectroscopy (Figure S9). Then, trypsin 
digestion (to cleave peptide chains mainly at the carboxyl side 
of Lys or Arg residues, unless there is a neighboring Pro resi-
due) was run, coupled with HPLC-MS/MS analysis. Full-scan 
and fragmentation data files were treated by using the Mas-
cotS database search engine, in order to find out which (if any) 
of the Lys residues located inside the hydrophobic binding 
sites of the protein became covalently modified by nucleo-
philic trapping of intermediates I or II (Chart 2). 
 
Chart 2. Chemical structures of the QM intermediates I and II 
together with the Lys trapping products 
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In the case of 1, an increment of ca. 170 amu was 
observed in peptides 99NECFLQHKDDNPNLPR114 (Mr exp. 
= 2165.9548, Mr calc. 2165.9589) and 
414KVPQVSTPTLVEVSR428 (Mr exp. = 1808.9629, Mr calc. 
= 1808.9673). The MS/MS analysis revealed modification of 
Lys106 (in subdomain IA). The MS/MS fragment ions showed 
an unmodified y ion series from y2 to y8, whereas an increment 
of m/z 298 amu was detected at Lys106 between y8 and y9 
corresponding to C11H7O2–Lys(–H2O). Besides, Lys414 (in 
sub-domain IIIA) was also modified, with a Lys106:Lys 414 
ratio of ca. 85. A suggested reaction mechanism is outlined in 
Scheme 2. A similar analysis for 2 showed an increment of 
196 amu in 191ASSAKQR197 (Mr exp = 942.4536, Mr calc. = 
942.4559) with covalent binding at Lys195 (located in sub-
domain IIA). In this case, the MS/MS fragment ions showed 
an unmodified y ion series from y3 to y6, while an increment of 
m/z 324 amu was detected at Lys195 between y2 and y3 corre-
sponding to C13H9O2–Lys(–H2O). Details of the ESI-MS/MS 
spectra and fragmentation patterns are shown in Figures S10-
S13 in the SI.  
Scheme 2. Proposed covalent modification mechanism for 1. 
 
Docking and Molecular Dynamics Simulations Studies. In 
an effort to understand in atomic detail the covalent modifica-
tion mechanism as well as to gain insight into the molecular 
basis of the  
observed selectivities, docking and Molecular Dynamics (MD) 
simulation studies were carried out. 
Binding of 1 to HSA and covalent addition to sub-domains IA 
and IIIA- The binding modes of ligand 1 in sub-domains IA 
and IIIA of HSA were first studied by molecular docking 
using the program GOLD25 version 5.2 and the available pro-
tein coordinates of the crystallographically determined HSA in 
complex with iophenoxic acid (PDB code 2YDF).26 This 
structure was chosen because two of the four molecules ob-
served are located close to Lys414. The positions of these 
molecules in sub-domain IIIA and of the ɛ-amino group of 
Lys106 in sub-domain IA were used to define the recognition 
site, and the radius was set to 8 Å. The highest score solutions 
obtained by docking were further analyzed by MD simulation 
studies in order to assess the stability and therefore the relia-
bility of the postulated binding. The monomer of the 1@HSA-
IA and 1@HSA-IIIA protein complexes in a truncated octahe-
dron of water molecules obtained with the molecular mechan-
ics force field AMBER27 was employed. The binding mode of 
the intermediate I was also studied by manual replacement of 
the ligand 1 with I in the binary 1@HSA-IA and 1@HSA-IIIA 
complexes, which was then subjected to 60 ns of dynamic 
simulation. Moreover, as for compound 1 the experimentally 
observed stoichiometry ligand vs HSA was 2:1, the ternary 
1+1@HSA complex was also considered. These studies re-
vealed sub-domain IA as the main binding pocket of 1, which 
will be discussed below. 
(a) Binary 1@HSA-IA complex. The results from the dynamic 
simulation of the 1@HSA-IA complex showed that the pro-
posed binding for 1 in sub-domain IA obtained by docking 
was reliable as this complex proved to be very stable (Figure 
2). Analysis of the root-mean-square deviation (rmsd) for the 
whole protein backbone (Cα, C, N and O atoms) calculated in 
the complex obtained from MD simulations studies revealed 
that it varies between 1.0−3.0 Å (average of 1.6 Å) and is 
relatively low for sub-domain IA (0.9−1.3 Å and an average of 
0.9 Å) (Figure S14). Ligand 1 would be anchored to sub-
domain IA of HSA via two hydrogen bonding interactions 
involving the phenol group and the main carbonyl group of 
Tyr148 and the amide side chain of Gln196 (Figures 2A and 
2B). Analysis of the variation of the relative distance between 
the atoms involved in the aforementioned hydrogen bonding 
interactions during the whole simulation revealed that 1 is well 
fixed in this pocket and its conformation properly controlled 
by these residues (Figure 2C). The CF3 moiety would be also 
located in the proximity of ɛ-amino group of Lys106 with an 
average distance of 5.3 Å during the simulation. In addition, 
ligand 1 would stablish numerous apolar interactions within 
the pocket, mainly involving the side chain of residues 
Leu103, Ala151, Leu250, Gly248, Cys246, Cys200 and the 
carbon side chain of Gln29. 
(b) Binary I@HSA-IA complex. As it is shown in Figure 2D, 
the results of our computational studies revealed that the in-
termediate I would be anchored to sub-domain IA of HSA via 
hydrogen bonding interaction with the main NH group of 
Ala151. The analysis of the relative distance between the C19 
atom (CF2 group) in I and the NZ atom of Lys106 and O17 
atom (carbonyl group) in I and NH group of Ala151 during 
the simulation revealed that this contact is present during 92% 
of the simulation with an average distance of 3.0 Å (Figure 
2E). Furthermore, the difluoromethide moiety in I would be 
located closer to the ɛ-amino group of Lys106 (average dis-
tance of 4.8 Å) than in the 1@HSA-IA complex (Figures 2C 
vs 2E). This proposed arrangement of the intermediate I ade-
quately explains the experimentally observed modification of 
Lys106.  
Once the intermediate I is generated by irradiation of 
the 1@HSA protein complex, covalent attachment would 
probably occur by nucleophilic attack of Lys106, which would 
be triggered by Asp108 acting as the general base and through 
the generation of the tyrosinate form of Tyr148 (Figure 2D). 
Thus, during 90% of the simulation a water molecule from the 
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bulk solvent remained fixed between the side chain of Asp108 
and Tyr148, with one of its protons engaged in a hydrogen 
bond with a carboxylate oxygen of Asp108 and one of its 
oxygen’s lone pairs accepting a hydrogen bond from the oxy-
gen atom of Tyr148. Under this arrangement, the tyrosinate 
could be generated and be the general base for the deprotona-
tion of Lys106 (nucleophile). The average distance between 
the NZ atom of Lys106 and the O atom of Tyr148, the O 
atom of Tyr148 and the O atom of the water molecule and 
the closest OD1/OD2 atoms (carboxyl group) of Asp108 
and the O atom of the water molecule during the whole 
simulation is 5.50 Å, 2.85 Å and 2.73 Å, respectively (Figure 
S15). The generation of catalytic tyrosinates in proteins by 
neighbor aspartate residues, either involving or not a water 
molecule, has previously been reported.28  
(c) Binary 1@HSA-IIIA complex. In general, the computation-
al studies carried out with the binary complex 1@HSA-IIIA 
reveal that in contrast to the binary complex 1@HSA-IA in 
which the CF3 group of the ligand is located close to the lysine 
that is modified, Lys106, the latter group would be placed 
further away from Lys414 (Figure 3). In particular, the aver-
age distance between the NZ atom of Lys414 and the C19 
atom (CF3 group) is of 9.0 Å during the 60 ns of simulation 
(Figure 3C, brown line). Moreover, the ligand would be locat-
ed in this pocket due to a strong hydrogen bonding with the 
main carbonyl group of Leu430 (average distance of 5.6 Å, 
Figure 3C, yellow line) as well as diverse apolar interactions 
with the side chain of residues Leu407, Val433, Leu453, 
Ala449, Ile388, Leu387 and Phe403, and the carbon chain of 
Asn391 (Figure 3B). Remarkably, the overall binding stability 
of ligand 1 in sub-domain IIIA seems to be lower than in sub-
domain IA in view of the greater mobility of the ligand in the 
pocket. This is because the binding pocket of the sub-domain 
IA is smaller and the polar interactions with the protein are 
stronger. These findings also revealed that the primary binding 
pocket of ligand 1 would be sub-domain IA. In this case, resi-
due Glu492, which is located close by Lys414, would act as 
the general base for the deprotonation of the lysine residue that 
undergoes covalent modification. The average distance be-
tween the NZ atom of Lys414 and the closest OE1/OE2 atoms 
(carboxylate grou) of Glu492 is 4.66 Å during the whole simu-
lation (Figure S16). 
(d) Ternary 1+1@HSA complex. The experimentally observed 
2:1 complex was also studied (Figure 3D). In general, no 
significant differences were observed in the binding of 1 to 
sub-domain IA in the ternary and binary complexes, locating 
in both cases the CF3 group of 1 in close contact to the ɛ-
amino group of Lys106 (average distance of 5.1 Å vs 5.3 Å, 
respectively) (Figures 3E vs 2C, black lines). More important-
ly, the presence of 1 in this pocket would significantly reduce 
the distance between the ɛ-amino group of Lys414 and the CF3 
group in 1 for covalent modification. These findings also 
reveal that: (1) sub-domain IA would be the primary binding 
pocket of 1, and (2) this last binding would have a positive 




Figure 2. Proposed binding mode of 1 (yellow) and the intermediate I (green) in sub-domain IA as obtained by MD simulation 
studies. (A) Overall view of the proposed binary 1@HSA-IA complex. Snapshot after 60 ns is shown. (B) Detailed view of the 
1@HSA-IA complex. (C) Variation of the relative distance between the C19 (CF3 group) and the O atom of 1 and the NZ atom of 
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Lys106, the O atom of Tyr148 and the NE2 atom of Gln196, respectively, in the 1@HSA-IA protein complex during 60 ns of simu-
lation. (D) Detailed view of the binary I@HSA-IA complex. Snapshot after 30 ns is shown. (E) Variation of the relative distance 
between the C19 (CF2 group) in I and the NZ atom of Lys106 and O17 atom (carbonyl group) in I and NH group of Ala151 in the 
I@HSA-IA protein complex during the whole simulation. Relevant side chain residues are shown and labelled. Lys106 and Asp108 
are shown in orange and yellow, respectively. Hydrogen bonding interactions are shown as red dashed lines. Note how for both 
complexes the lysine residue that is covalently modified (Lys106) is located very close to the fluoromethide moiety and the phenol 
group in 1 and the ketone group in I would be anchored in the pocket by strong hydrogen bonding interactions. 
 
 
Figure 3. Proposed binding mode of 1 in binary 1@HSA-IIIA and ternary 1+1@HSA complexes as obtained by MD simulation 
studies. (A) Overall view of the proposed binary 1@HSA-IIIA complex. Snapshot after 50 ns is shown. (B) Detailed view of the 
1@HSA-IIIA complex. (C) Variation of the relative distance between the C19 (CF3 group) and O atom of 1 and the NZ atom of 
Lys414 and the O atom of Leu430, respectively, in the 1@HSA-IIIA protein complex during 60 ns of simulation. (D) Overall view 
of the proposed ternary 1+1@HSA complex. Snapshot after 20 ns is shown. (E) Variation of the relative distance between the C19 
(CF3 group) of 1 and the NZ atom of Lys106 and Lys414 in the 1@HSA-IIIA and 1+1@HSA complexes, respectively, during 60 
ns of simulation. Relevant side chain residues are shown and labelled. Lys414 and Glu492 are shown in orange and yellow, respec-
tively. Hydrogen bonding interactions are shown as red dashed lines. Note how Lys414 is located closer to the CF3 group in 1 in the 
ternary 1+1@HSA complex than in the binary one.  
 
The analysis of the rmsd for the whole protein backbone (Cα, 
C, N and O atoms) and the sub-domains IA and IIIA calculat-
ed in the ternary 1+1@HSA complex also corroborate the 
increased stability of these protein pockets (Figure S9D). The 
computational results explain the abovementioned photophys-
ical and proteomic experimental results. Moreover, the MD 
simulation studies carried out with the corresponding ternary 
adducts revealed that the intermediate I would be rapidly 
trapped, in particular by Lys414 as its mobility in this pocket 
is very significant. 
Binding of 2 to HSA and covalent addition to sub-domain IIA 
− As for ligand 1, the binding mode of ligand 2 in sub-domain 
IIA of HSA was first studied by molecular docking using the 
protein coordinates found in the crystal structure of HSA in 
complex with oxyphenbutazone (PDB code 2BXB29). The 
ligand in this structure is located close to the experimentally 
observed modified Lys195 residue. It is important to highlight 
that an analysis of the residues surrounding Lys195 revealed 
that this residue is located nearby another lysine residue, 
Lys199, whose modification was not observed (Figure 4). 
Considering that when two lysine residues are located very 
close in space, usually only one of them is protonated at phys-
iological pH, simulation studies with the two possible protona-
tion states of both lysine residues were performed. The best 
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results were obtained considering neutral Lys195 (nucleo-
phile) and protonated Lys199, which would be also in agree-
ment with the experimental results. Furthermore, although the 
obtained binding mode reveals that both residues are close in 
distance to the CF3 group in 2, the arrangement of the side 
chain of Lys199 observed during 60 ns of simulation revealed 
to be geometrically inappropriate for nucleophilic attack once 
the intermediate II would be generated (Figures 4B and 4D). 
The ɛ-amino group in Lys199 is predicted to be parallel to the 
ligand during the whole simulation rather than facing to the 
difluoromethide group in II for chemical modification. The 
binary 2@HSA-IIA complex probed to be very stable, con-
firming the reliability of the proposed binding (Figure S17). 





Figure 4. Proposed binding mode of the ligand 2 (violet) and the intermediate II (green) in sub-domain IIA as obtained by MD 
simulation studies. (A) Overall view of the proposed binary 2@HSA-IIA complex. Snapshot after 60 ns is shown. (B) Detailed 
view of the binary 2@HSA-IIA complex. (C) Variation of the relative distance between the C23 atom (CF2 group) and the NZ atom 
of Lys195 in the II@HSA-IIA protein complex during 60 ns of simulation. (D) Detailed view of the II@HSA-IIA adduct. Snapshot 
after 20 ns is shown. Note how Lys195 is well located for nucleophilic attack. Relevant side chain residues are shown and labelled. 
Hydrogen bonding interactions of the intermediate II are shown as red dashed lines. 
 
within the pocket were not identified. In this case, the polar 
interactions of the phenol moiety in 2, which fixes this ligand 
in the pocket, would be mediated by water molecules (not 
shown). Moreover, ligand 2 would be embedded in a large 
apolar pocket involving residues Val343, Val344, Val482, 
Leu347, Leu481, Val455, Leu198, Phe206, Phe211, Ala210, 
Trp214 and the carbon side chain of Asp451 and Ser202. 
The intermediate II generated by irradiation of the 2@HSA-
IIA protein complex would have a similar binding mode as 
ligand 2 (Figure 4D). As for 2, no direct polar contacts be-
tween II and the protein were observed. Instead, the ketone 
group in II would interact with the side chain of Ser202 and 
Arg209 through water molecules. Under this arrangement, the 
ɛ-amino group of Lys195 is well located for nucleophilic 
attack to the difluoromethide moiety in II. Thus, the analysis 
of the variation of the relative distance between the C23 atom 
(CF2 group) and the NZ atom of Lys195 in the II@HSA-IIA 
protein adduct during 60 ns of simulation revealed an average 
distance of 5.7 Å (Figure 4C). 
CONCLUSIONS 
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The combined experimental and theoretical results suggest 
that quinone methides photogenerated from trifluoro-
methylphenols can be appropriate latent electrophiles to 
achieve selective lysine targeting. Thus, 1 and 2 form ground-
state complexes with HSA, characterized by a long-
wavelength absorption band with maxima at ca. 320 nm, 
which allows their selective excitation, resulting in a well-
defined emission appearing at ca. 420 nm. Photolysis of the 
complexes produces a covalently modified protein, whose 
proteomic analysis reveals selective targeting of Lys 106 and, 
to a lesser extent, Lys 414, in the case of ligand 1; by contrast, 
Lys 195 becomes selectively modified upon irradiation of 
ligand 2 within HSA. The results of our MD simulation stud-
ies revealed that not only the ligands but also the photogener-
ated intermediates form stable complexes with the identified 
pockets of HSA, which would explain the selective modifica-
tion of the internal lysine residues, Lys106, Lys414, and 
Lys195. The computational studies performed with the binary 
1@HSA-IA and 1@HSA-IIIA and ternary 1+1@HSA com-
plexes reveal sub-domain IA as the main binding pocket of 1. 
Ligand 1 would be anchored to this pocket via two hydrogen 
bonding interactions involving the phenol group and the main 
carbonyl group of Tyr148 and the amide side chain of Gln19. 
After irradiation, the photogenerated intermediate I would be 
fixed to this pocket via hydrogen bonding interaction with the 
main NH group of Ala151 allowing the difluoromethide moie-
ty in I to be located close to the ɛ-amino group of Lys106 for 
nucleophilic attack. In addition, binding to sub-domain IA 
would have a positive cooperative effect that would favor the 
binding to sub-domain IIIA. This is in agreement with the 
experimentally observed modification of Lys106 and Lys414 
residues in a ratio of ca. 85:1, respectively. On the other hand, 
the intermediate II photogenerated from ligand 2 would bind 
to sub-domain IIA via polar contacts with the side chain of 
Ser202 and Arg209 mediated by water molecules. Under this 
arrangement, the ɛ-amino group of Lys195 would be well 
located for nucleophilic attack to the difluoromethide moiety 
in II.  
EXPERIMENTAL SECTION 
General. Human serum albumin and 4’-hydroxy-4-
biphenylcarboxylic acid were commercially available. Spec-
trophotometric, HPLC or reagent grade solvents were used 
without further purification. Buffered saline solutions at pH 
7.4 and pH 12 were prepared by dissolving commercially 
available tablets in deionized water. Ligands 4-
trifluoromethyl-1-naphthol (1) and 4-(4-
trifluorometylphenyl)phenol (2), were synthesized following 
previously reported procedures.30  
Absorption and emission measurements. Optical spectra at 
different media were recorded on a JASCO V-630 spectropho-
tometer. Steady-state emission and excitation spectra were 
recorded on a JASCO FP-8500 spectrofluorometer system, 
provided with a monochromator in the wavelength range of 
200-850 nm, at 22°C. Time-resolved fluorescence measure-
ments were performed with an EasyLife V spectrometer from 
OBB (Palaiseau, France), equipped with a pulsed LED (λexc 
295 nm) as excitation source. The kinetic traces were fitted by 
one monoexponential decay function, using a deconvolution 
procedure to separate them from the lamp pulse profile. Exper-
iments were performed on solutions of known concentration in 
different media, employing 10 × 10 mm2 quartz cells with 4 
mL capacity.  
Laser flash photolysis measurements. Experiments were 
carried out with a pulsed Nd:YAG Laser system with 355 nm 
as excitation wavelength, 0.6 cm as beam diameter and a pulse 
duration of 10 ns. The energy was set at 15 mJ/pulse. The 
apparatus consisted of the pulsed laser, a xenon lamp, a mono-
chromator, and a photomultiplier. Samples of 1 and 2 in the 
presence of  5 equivalents of HSA were placed in 10 mm × 10 
mm quartz cells. The absorbance of the complexes at the exci-
tation wavelength was kept at 0.25. Experiments were per-
formed at 22°C. 
Steady-state photolysis experiments. Irradiations of 1 or 2 (5 
× 10−5 M) were performed in PBS in the presence or absence 
of HSA (ligand/protein 1:5 molar ratio) in a multilamp photo-
reactor containing low pressure mercury lamps (14 × 8 W), 
with emission maximum at λ= 300 nm, through Pyrex. The 
course of the process was followed by monitoring the changes 
in the fluorescence spectra of the reaction mixtures at increas-
ing times. 
Protein Digestion and LC-ESI-MS/MS Analysis. Human 
serum albumin (HSA) was enzymatically digested into smaller 
peptides using trypsin. Subsequently, these peptides were 
analyzed using nanoscale liquid chromatography coupled to 
tandem mass spectrometry (nano LC-MS/MS). Briefly, 20 µg 
of sample were taken (according to Qubit quantitation) and the 
volume was set to 20 µL. Digestion was achieved with se-
quencing grade trypsin (Promega) according to the following 
steps: i) 2 mM DTT in 50 mM NH4HCO3 V = 25 µL, 20 min 
(60 °C); ii) 5.5 mM IAM in 50 mM NH4HCO3 V=30 µL, 30 
min (dark); iii) 10 mM DTT in 50 mM NH4HCO3 V = 60 µL, 
30 min; iv) Trypsin (Trypsin: Protein ratio 1:20 w/w) V = 64 
µL, overnight 37 °C. Digestion was stopped with 7 µL 10% 
TFA (Cf protein ca 0.28 µg/µL). Next, 5 µL of sample (except 
the main bands) were loaded onto a trap column (NanoLC 
Column, 3µ C18-CL, 350 um × 0.5 mm; Eksigent) and desalt-
ed with 0.1% TFA at 3 µL/min during 5 min. The peptides 
were then loaded onto an analytical column (LC Column, 3 µ 
C18-CL, 75 um × 12 cm, Nikkyo) equilibrated in 5% acetoni-
trile 0.1% formic acid. Elution was carried out with a linear 
gradient of 5 to 45% B in A for 30 min (A: 0.1% formic acid; 
B: acetonitrile, 0.1% formic acid) at a flow rate of 300 
µL/min. Peptides were analyzed in a mass spectrometer 
nanoESI qQTOF (5600 TripleTOF, ABSCIEX). The tri-
pleTOF was operated in information-dependent acquisition 
mode, in which a 0.25-s TOF MS scan from 350–1250 m/z 
was performed, followed by 0.05-s product ion scans from 
100-1500 m/z on the 50 most intense 2-5 charged ions. Pro-
teinPilot v4.5. (ABSciex) search engine default parameters 
were used to generate peak list directly from 5600 TripleTOF 
wiff files. The obtained mgf was used for identification with 
MASCOT (v 4.0, Matrix- Science). Database search was 
performed on SwissProt database. Searches were done with 
tryptic specificity allowing one missed cleavage and a toler-
ance on the mass measurement of 100 ppm in MS mode and 
0.6 Da in MS/MS mode. 
Docking studies. They were carried out using program GOLD 
5.2.223 and the protein coordinates found in the crystal struc-
ture of HSA in complex with: (a) oxyphenbutazone (PDB 
code 2BXB29) for 2 and iophenoxic acid (PDB code 2YDF24) 
for 1. These structures were selected since the observed lig-
Page 8 of 12
ACS Paragon Plus Environment































































ands are located in the same region where the lysine residues 
covalently modified by 1 and 2 were observed. Ligand geome-
tries were minimized using the AM1 Hamiltonian as imple-
mented in the program Gaussian 0931 and used as MOL2 files. 
Each ligand was docked in 25 independent genetic algorithm 
(GA) runs, and for each of these a maximum number of 
100000 GA operations were performed on a single population 
of 50 individuals. Operator weights for crossover, mutation 
and migration in the entry box were used as default parameters 
(95, 95, and 10, respectively), as well as the hydrogen bonding 
(4.0 Å) and van der Waals (2.5 Å) parameters. The position of 
the side chain of the experimentally observed modified residue 
was used to define the active-site and the radius was set to 8 
Å. All crystallographic water molecules and the ligands were 
removed for docking. The “flip ring corners” flag was 
switched on, while all the other flags were off. The GOLD 
scoring function was used to rank the ligands in order to fit-
ness. 
Molecular dynamic simulations. (a) Ligand minimization. 
The ligand geometries of the highest score solution obtained 
by docking were minimized using a restricted Hartree–Fock 
(RHF) method and a 6–31G(d) basis set, as implemented in 
the ab initio program Gaussian 09. Partial charges were de-
rived by quantum mechanical calculations using Gaussian 09, 
as implemented in the R.E.D. Server (version 3.0),32 according 
to the RESP33 model. Ligand coordinates obtained by docking 
were employed as starting point for MD simulations. The 
missing bonded and non-bonded parameters were assigned, by 
analogy or through interpolation, from those already present in 
the AMBER34 database (GAFF35). 
(b) Generation and minimization of the complexes. Simula-
tions of the HSA/2 and HSA/1 binary complexes were carried 
out using the enzyme geometries in PDB codes 2BXB and 
2YDF, respectively. Computation of the protonation state of 
titratable groups at pH 7.0 was carried out using the H++ Web 
server.36 Addition of hydrogen and molecular mechanics pa-
rameters from the ff14SB37 and GAFF force fields, respective-
ly, were assigned to the protein and the ligands using the LEaP 
module of AMBER Tools 15.29 As a result of this analysis: (i) 
His535 was protonated in δ position; (ii) His3, His9, His39, 
His146, His242, His288, His440, His464 and His510 were 
protonated in ε position; (iii) His67, His105, His128, His247, 
His338 and His367 were protonated in δ and ε positions. The 
protein was immersed in a truncated octahedron of ∼25000 
TIP3P water molecules and neutralized by addition of sodium 
ions. The system was minimized in five stages: (a) minimiza-
tion of poorly unsolved residues: (i) for PDB 2BXB: 12, 33, 
41, 51, 56, 60, 73, 81, 82, 84, 94, 95, 97, 111, 114, 174, 186, 
190, 205, 209, 225, 227, 240, 250, 275, 276, 277, 297, 301, 
313, 317, 321, 359, 390, 402, 436, 439, 444, 466, 513, 519, 
524, 532, 536, 538, 541, 545, 550, 551, 560, 562, 564, 565, 
574 and 580; and (ii) for PDB 2YDF: 12, 16, 31, 33, 41, 48, 
56, 60, 64, 69, 77, 81, 82, 84, 93, 94, 95, 97, 98, 104, 109, 
114, 115, 119, 121, 132, 136, 137, 141, 159, 160, 162, 167, 
174, 178, 186, 190, 195, 205, 262, 269, 276, 277, 280, 301, 
302, 305, 313, 314, 317, 351, 359, 365, 372, 376, 389, 390, 
397, 402, 425 ,432, 436, 439, 444, 459, 466, 500, 502, 503, 
505, 507, 509, 510, 512, 513, 516, 520, 524, 525, 536, 541, 
543, 545, 548, 549, 550, 551, 554, 560, 562, 563, 564, 565, 
568, 570, 571, 573, 574, 575, 580 and 582 (1000 steps, first 
half using steepest descent and the rest using conjugate gradi-
ent); (b) minimization of the ligand (1000 steps, first half 
using steepest descent and the rest using conjugate gradient); 
(c) minimization of the solvent and ions (5000 steps, first half 
using steepest descent and the rest using conjugate gradient); 
(d) minimization of the side chain residues, waters and ions 
(5000 steps, first half using steepest descent and the rest using 
conjugate gradient); (e) final minimization of the whole sys-
tem (5000 steps, first half using steepest descent and the rest 
using conjugate gradient). A positional restraint force of 50 
kcal mol–1 Å–2 was applied to not minimized residues of the 
protein during the stages a-c and to α carbons during the stage 
d, respectively.  
(c) Simulations. MD simulations were performed using the 
pmemd.cuda_SPFP38-40 module from the AMBER 14 suite of 
programs. Periodic boundary conditions were applied and 
electrostatic interactions were treated using the smooth parti-
cle mesh Ewald method (PME)41 with a grid spacing of 1 Å. 
The cutoff distance for the non-bonded interactions was 9 Å. 
The SHAKE algorithm42 was applied to all bonds containing 
hydrogen using a tolerance of 10−5 Å and an integration step of 
2.0 fs. The minimized system was then heated at 300 K at 1 
atm by increasing the temperature from 0 K to 300 K over 100 
ps and by keeping the system at 300 K another 100 ps. A 
positional restraint force of 50 kcal mol–1 Å–2 was applied to 
all α carbons during the heating stage. Finally, an equilibration 
of the system at constant volume (200 ps with positional re-
straints of 5 kcal mol–1 Å–2 to α alpha carbons) and constant 
pressure (another 100 ps with positional restraints of 5 kcal 
mol–1 Å–2 to α alpha carbons) were performed. The positional 
restraints were gradually reduced from 5 to 1 mol–1 Å–2 (5 
steps, 100 ps each), and the resulting systems were allowed to 
equilibrate further (100 ps). Unrestrained MD simulations 
were carried out for 100 ns. System coordinates were collected 
every 10 ps for further analysis. The molecular graphics pro-
gram PyMOL43 was employed for visualization and depicting 
ligand/protein structures. The cpptraj module in AMBER 14 
was used to analyse the trajectories and to calculate the root-
mean-square deviations (rmsd) of the protein during the simu-
lation.44 
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